Compare · GILD vs LXEO
GILD vs LXEO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $190.38B, about 882.3x LXEO ($215.8M).
- Over the past year, GILD is up 32.2% and LXEO is down 69.5% - GILD leads by 101.6 points.
- LXEO has been more active in the news (12 items in the past 4 weeks vs 4 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Gilead Sciences Inc.
- Lexeo Therapeutics Inc.
- Price
- $155.78-1.04%
- $2.68-2.55%
- Market cap
- $190.38B
- $215.8M
- 1M return
- +3.16%
- -36.04%
- 1Y return
- +32.16%
- -69.48%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2023
- News (4w)
- 4
- 12
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
Latest LXEO
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Financial Officer Tamayo Louis Edward
- Chief Operating Officer Otero Jose Manuel was granted 2,110 shares, increasing direct ownership by 2% to 138,288 units (SEC Form 4)
- Chief Medical Officer Bhalla Narinder Pal was granted 2,714 shares, increasing direct ownership by 3% to 84,908 units (SEC Form 4)
- Chief Executive Officer Townsend Richard Nolan was granted 2,306 shares, increasing direct ownership by 0.62% to 376,778 units (SEC Form 4)
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum